NKGen Biotech presented clinical data on troculeucel, an autologous expanded natural killer cell therapy, in Alzheimer's disease, Parkinson's disease and frontotemporal dementia, reporting effects on inflammatory markers and abnormal proteins in cerebrospinal fluid. The approach targets immune-driven brain inflammation rather than amyloid plaque clearance, the mechanism behind most current Alzheimer's drugs. The therapy remains investigational with no approved product.
Key Points
- Patient-derived NK cells expanded ex vivo, reinfused to modulate neuroinflammation
- Cerebrospinal fluid markers tracked across Alzheimer's, Parkinson's, frontotemporal dementia
- Asian regulatory pathways may precede US approval; therapy remains investigational
Longevity Analysis
Extended lifespan without preserved cognition is a poor bargain, and the amyloid-clearance paradigm has delivered modest returns against that standard. Repositioning immune surveillance cells from tumor patrol to inflammation control reframes neurodegeneration as a failure of defense and clearance in the aging brain rather than a protein-deposition problem alone. Cerebrospinal fluid markers shifting before cognitive tests register change points to the wider principle that the body signals dysfunction well ahead of symptoms, provided the right measurements are being read.
Original published by Longevity.Technology, by Kyle Umipig.